CAS 951151-97-6

(E)-1-(4-(6-amino-5-((methoxyimino)methyl)pyrimidin-4-yloxy)-2-chlorophenyl)-3-ethylurea

CAS: 951151-97-6

Formula: C₁₅H₁₇ClN₆O₃

Purity: 98%

Molecular weight: 364.7869

Ref: IN-DA01DNTJ

1-(4-((6-Amino-5-((Methoxyimino)Methyl)Pyrimidin-4-Yl)Oxy)-2-Chlorophenyl)-3-Ethylurea

CAS: 951151-97-6

1-(4-((6-Amino-5-((Methoxyimino)Methyl)Pyrimidin-4-Yl)Oxy)-2-Chlorophenyl)-3-Ethylurea

Purity: 98%

Molecular weight: 364.79g/mol

Ref: 54-OR1023011

JNJ-38158471

CAS: 951151-97-6

JNJ-38158471

Purity: ≥95%

Molecular weight: 364.79g/mol

Ref: 54-BUP08065

JNJ-38158471

CAS: 951151-97-6

Ref: 7W-GW9904

JNJ-38158471

CAS: 951151-97-6

JNJ-38158471 (CS-2660), a highly selective, orally available, well tolerated VEGFR2 inhibitor, inhibits closely related tyrosine kinases such as Ret and Kit .

Formula: C₁₅H₁₇ClN₆O₃

Purity: 97.08%

Color and Shape: Solid

Molecular weight: 364.79

Ref: TM-T22349

JNJ-38158471

CAS: 951151-97-6

JNJ-38158471 is a tyrosine kinase inhibitor that has been shown to have anticancer activity. It can be used for the treatment of cancers, including primary resistance. JNJ-38158471 modulates the activity of growth factors, such as vascular endothelial growth factor and hepatocyte growth factor, which are involved in tumor angiogenesis and tumor cell proliferation. This drug also interacts with factor receptors on cells, which may lead to the termination of their signaling pathways. The oral formulation of JNJ-38158471 has been found to be safe and well tolerated in preclinical studies in mice. This drug is also selective for cancer cells, not affecting normal cells.

Formula: C₁₅H₁₇ClN₆O₃

Purity: Min. 95%

Molecular weight: 364.79 g/mol

Ref: 3D-BNB15197